Secretogranin II (SCG2) ELISA Kits

Human Secretogranin II (SCG2) interaction partners

1. serum levels of CgA, CgB, and SgII were determined in Parkinson's disease patients and assessed their association with disease severity.

2. Differential Reovirus-Specific and Herpesvirus-Specific Activator Protein 1 Activation of Secretogranin II Leads to Altered Virus Secretion.

3. present data show that SgII is highly expressed in advanced prostate cancer and may contribute to the neuroendocrine differentiation by promoting the formation of secretory granules and the proliferation of PCa cells.

4. SN induces MUC5AC hypersecretion in a dose- and time-dependent manner; moreover, the MUC5AC over synthesis induced by SN is strongly associated with the enhanced binding of EGF to NRP1

5. Topical secretoneurin gene therapy accelerates diabetic wound healing by interaction between heparan-sulfate proteoglycans and basic FGF.

6. Manserin may serve as a marker of prostate cancer progression.

7. CgA, CgB, and secretoneurin are detectable in feces, and collagenous colitis patients express higher values than patients with inflammatory bowel disease and controls. In treatment, fecal secretoneurin decreased to control levels in collagenous colitis.

8. In vivo secretoneurin improves left ventricular function, inhibits remodeling, and reduces scar formation; in the infarct border zone, secretoneurin induces coronary angiogenesis.

9. Circulating Levels of SgII are Increased in Patients with chronic, stable heart failure.

10. Data describe the gene expression and protein production of SgII in normal adrenal glands and pheochromocytomas with the goal to examine the molecular mechanisms leading to the marked variations in the expression of EM66 in tumoral chromaffin tissue.

11. This short review deals with investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III.

12. More SgII immunoreactive cells were observed in phaeochromocytomas.

13. Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin.

14. secretogranin II-derived peptide EM66 generated in human tumoral chromaffin tissue; significant difference in EM66 concentrations between benign and malignant pheochromocytomas

15. the high concentration of secretoneurin in the aqueous humor indicates a significant role of this peptide

16. a variant of Secretogranin II has a role in regulation by PHOX2 transcription factors and in hypertension

17. Results suggest that secretogranin II represents a key AP-1-regulated protein that counteracts nitric oxide toxicity and mediates neuronal differentiation of neuroblastoma cells.

18. Increased concentrations of SgII, especially the N-terminal part of secretoneurin could be measured in plasma from patients with endocrine pancreatic tumours.

19. Suppression of Pdcd4 resulted in an increased release of CgA and Sg II and was accompanied by an up-regulation of intracellular PC1.

20. semiquantitative immunocytochemistry for secretogranin II in amyotrophic lateral sclerosis.

Mouse (Murine) Secretogranin II (SCG2) interaction partners

1. Scg2 is a major secretory target of REST with a cell differentiation-enhancing activity in neural stem cells.

2. Topical secretoneurin gene therapy accelerates diabetic wound healing by interaction between heparan-sulfate proteoglycans and basic FGF.

3. Scg2 is a good candidate for the signal integrator required for activity-dependent plasticity such as associative learning and memory.

4. SgII binds directly to the secretory granule membrane and controls intracellular retention of proopiomelanocortin in AtT-20 cells.

5. SgII mRNA levels were 10.5 fold upregulated in the left ventricle of animals with myocardial infarction and heart failure.

6. it was proven that ScgII cannot be categorized as an activity marker, but more likely plays a role in visual system plasticity by modulating a range of neurotransmitters and neuropeptides

7. SN activates the protein kinase A (PKA) and cAMP-induced ERK signaling pathways in the LH-secreting mouse LbetaT2 pituitary cell line

8. The wide subcellular localization of secretogranin II in mouse brain may reflect diverse release sites of neuropeptides and secretorneurin, or suggests its role in the sorting and packaging of molecules other than neuropeptides in non-LDCV compartments.

9. SCG2, as well as SCG3, may be a potential regulator of food intake based on its capacity to accumulate appetite-related hormones into secretory granules.

Cow (Bovine) Secretogranin II (SCG2) interaction partners

1. secretogranin II-derived peptide EM66 may act downstream of the trans-synaptic stimulation of the adrenal medulla by neurocrine factors

2. Results show the localization of secretogranin II (SgII) in the nucleus, more specifically, in the IP3-sensitive nucleoplasmic Ca2+ store vesicles along with CGB and the IP3 receptors.

Pig (Porcine) Secretogranin II (SCG2) interaction partners

1. Comparative sequencing and EST analysis revealed nine SNPs in porcine SCG2 cDNA, including seven SNPs in the coding region and two SNPs in the 3' UTR.